Effects of pycnogenol on cardiometabolic health: A systematic review and meta-analysis of randomized controlled trials

Malekahmadi, Mahsa; Moghaddam, Omid Moradi; Firouzi, Safieh; Daryabeygi-Khotbehsara, Reza; Islam, Sheikh Mohammed Shariful; Norouzy, Abdolreza; Soltani, Sepideh

doi:10.1016/j.phrs.2019.104472

Cited by 16 publications

(24 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, there was an increase of ALP levels in both treatment groups, which to be greater in placebo group compared to oligopin. Overall, based on our results and previous study oligopin did no show toxic effects on liver function (20). The hypoglycemic effects of pine bark extract may be related to inhibition of alpha glycosidase activity in the small intestinal brush border due to procyanidins ( avonoids), independent of effect on insulin secretion (21,22).…”

Section: Discussionsupporting

confidence: 78%

“…Our nding that oligopin failed to signi cantly in uence cardiovascular disease risk factors (insulin, fasting glucose, lipid pro les and hs-CRP) is an observation that has been recorded previously in overweight and obese adults (19). The meta-analysis by Malekamadi et al and collaborators, showing several biological effect of this extract such as decreased glycemia and lipid pro le, decreased weight and blood pressure and reduced hs-CRP level, was faulted by pooling low quality and high heterogeneity studies (20). Notably, the Meta -analysis of randomized trials indicated that pycnogenol signi cantly raised AST levels and decreased GGT concentration by 1.53 U/I (20).…”

Section: Discussionmentioning

confidence: 96%

“…The meta-analysis by Malekamadi et al and collaborators, showing several biological effect of this extract such as decreased glycemia and lipid pro le, decreased weight and blood pressure and reduced hs-CRP level, was faulted by pooling low quality and high heterogeneity studies (20). Notably, the Meta -analysis of randomized trials indicated that pycnogenol signi cantly raised AST levels and decreased GGT concentration by 1.53 U/I (20). In the present study we did not observe any signi cant changes in ALT and AST levels in oligopin group.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Effect of Oligopin Supplementation on Polycystic Ovary Syndrome: A Randomized Controlled Trial

Mansour¹,

Sanginabadi²,

Mohajeri-Tehrani³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: A double blind clinical trial was performed to evaluate whether polycystic ovary syndrome (PCOS)-specific serum markers and metabolic parameters would change in women with PCOS during three months administration of oligopin. Methods: In this double-blind multicenter trial, we randomly assigned 80 PCOS women, in a 1:1 ratio, to receive oligopin (n= 40) or placebo (n = 40) for up to 3 months. As PCOS- specific outcomes, we investigated changes in testosterone, sex hormone binding globulin (SHBG), free androgen index (FAI), dehydroepiandrosterone (DHEA), follicle-stimulating hormone (FSH) and increase luteinizing hormone (LH). Secondary end points were metabolic (fasting glycaemia, hemoglobin A1c (HbA1c), lipids, insulin resistance (HOMA-IR)), anthropometrics parameters and blood pressure from baseline to end of treatment. We investigate serum transaminase, alkaline phosphatase (ALP), creatinine (Cr) and blood urea nitrogen (BUN) levels as hepatic and kidney outcomes, respectively. Results: PCOS-specific serum parameters did not change during three months administration of oligpin (p > 0.05) except for small increase in FSH levels (p=0.03). Oligopin neither changed the metabolic profile nor the anthropometric parameters or blood pressure. ALP levels significantly increased in placebo group compared with oligopin (p=0.01). Conclusion: Oligopin supplementation does not seem to be exerting a beneficial effect on both hormonal and metabolic parameters in women with PCOS.The study was registered at www.irct.ir with the identifier number of IRCT20140406017139N3.Registered 22 December 2018 - Retrospectively registered.

show abstract

Section: Discussionsupporting

confidence: 78%

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of Oligopin Supplementation on Polycystic Ovary Syndrome: A Randomized Controlled Trial

Mansour¹,

Sanginabadi²,

Mohajeri-Tehrani³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Recently, we conducted a systematic review and metaanalysis of clinical trials that used PYC in chronic diseases [32]. Our meta-analysis revealed that PYC supplementation may have beneficial effects on glycolipid metabolism by reducing fasting glucose, HbA1c, LDL, and enhancing HDL.…”

Section: Pycnogenolmentioning

confidence: 99%

Evaluation of the effects of pycnogenol (French maritime pine bark extract) supplementation on inflammatory biomarkers and nutritional and clinical status in traumatic brain injury patients in an intensive care unit: A randomized clinical trial protocol

Malekahmadi

Moghaddam

Islam

et al. 2020

Trials

Self Cite

View full text Add to dashboard Cite

Background: Traumatic brain injury (TBI) is one of the major health and socioeconomic problems in the world. Immune-enhancing enteral formula has been proven to significantly reduce infection rate in TBI patients. One of the ingredients that can be used in immunonutrition formulas to reduce inflammation and oxidative stress is pycnogenol. Objective: The objective of this work is to survey the effect of pycnogenol on the clinical, nutritional, and inflammatory status of TBI patients. Methods: This is a double-blind, randomized controlled trial. Block randomization will be used. An intervention group will receive pycnogenol supplementation of 150 mg for 10 days and a control group will receive a placebo for the same duration. Inflammatory status (IL-6, IL-1β, C-reactive protein) and oxidative stress status (malondialdehyde, total antioxidant capacity), at the baseline, at the 5th day, and at the end of the study (10th day) will be measured. Clinical and nutritional status will be assessed three times during the intervention. The Sequential Organ Failure Assessment (SOFA) questionnaire for assessment of organ failure will be filled out every other day. The mortality rate will be calculated within 28 days of the start of the intervention. Weight, body mass index, and body composition will be measured. All analyses will be conducted by an initially assigned study arm in an intention-to-treat analysis.Discussion: We expect that supplementation of 150 mg pycnogenol for 10 days will improve clinical and nutritional status and reduce the inflammation and oxidative stress of the TBI patients.Trial registration: This trial is registered at clinicaltrials.gov (ref: NCT03777683) at 12/13/2018.

show abstract

“…Recently, we conducted a systematic review and meta-analysis of clinical trials that used PYC in chronic diseases (33). Our meta-analysis revealed that PYC supplementation may have beneficial effects on glycolipid metabolism by reducing fasting glucose, HbA1c, LDL and enhancing HDL.…”

Section: Pycnogenolmentioning

confidence: 99%

Evaluation the effects of pycnogenol (French maritime pine bark extract) supplementation on the inflammatory biomarkers, nutritional and clinical status in traumatic brain injury patients, in Intensive Care Unit; A Randomized Clinical Trial protocol

Malekahmadi

Moghaddam

Islam

et al. 2019

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Traumatic brain injury (TBI) is one of the major health and socioeconomic problems in the world. Immune-enhancing enteral formula has been proven to significantly reduce infection rate in TBI patient. One of the ingredients that can be used in immunonutrition formulas to reduce inflammation and oxidative stress is pycnogenol. Objective: surveying the effect of pycnogenol on the clinical, nutritional and inflammatory status of TBI patients. Methods: This is double-blind, randomized controlled trial . Block randomization will be used. Intervention group will receive pycnogenol supplementation of 150 mg for 10 days. Control group will receive placebo for the same duration. Inflammatory status (IL-6, IL- 1β, C-reactive protein) and oxidative stress status (Malondialdehyde, total antioxidant capacity), at the base line, at the 5 th day and at the end of the study (10 th day) will be measured. Clinical and nutritional status will be assessed three times during the intervention. SOFA (sequential organ failure assessment) questionnaire for assessment of organ failure will be filled out every other day. The mortality rate will be calculated within 28 days of the start of the intervention. Weight, body mass index and body composition will be measured. All analyses will be conducted by initially assigned study arm in an intention-to-treat analysis. Discussion: We expect that supplementation of 150 mg pycnogenol for 10 days will improve clinical and nutritional status and reduce the inflammation and oxidative stress of the TBI patients.

show abstract

Effects of pycnogenol on cardiometabolic health: A systematic review and meta-analysis of randomized controlled trials

Cited by 16 publications

References 42 publications

Effect of Oligopin Supplementation on Polycystic Ovary Syndrome: A Randomized Controlled Trial

Effect of Oligopin Supplementation on Polycystic Ovary Syndrome: A Randomized Controlled Trial

Evaluation of the effects of pycnogenol (French maritime pine bark extract) supplementation on inflammatory biomarkers and nutritional and clinical status in traumatic brain injury patients in an intensive care unit: A randomized clinical trial protocol

Evaluation the effects of pycnogenol (French maritime pine bark extract) supplementation on the inflammatory biomarkers, nutritional and clinical status in traumatic brain injury patients, in Intensive Care Unit; A Randomized Clinical Trial protocol

Contact Info

Product

Resources

About